Background. Botulism manifests with cranial nerve palsies and flaccid paralysis in children and adults. Botulism must be rapidly identified and treated; however, clinical presentation and treatment outcomes of noninfant botulism in children are not well described.
Botulism is a potentially fatal neuroparalytic disorder caused by botulinum toxin, produced by Clostridium botulinum or related species [1] . Botulism can be categorized by mode of transmission and toxin production into several types-foodborne, wound, infant, noninfant intestinal, and iatrogenic-with varied levels of epidemic potential. Foodborne botulism is caused by ingestion of preformed toxin in food; outbreaks occur periodically [2] . Wound botulism is caused by colonization of a wound by C. botulinum with in situ toxin production; it has low epidemic potential. Infant botulism is caused by colonization of the immature infant intestine by C. botulinum and subsequent toxin production; it is a sporadic disease without epidemic potential that occurs in individuals aged <1 year. It is important to note that infants (<1 year of age) are also susceptible to foodborne botulism. Both noninfant intestinal botulism, also due to intestinal colonization and toxin production, and iatrogenic botulism, systemic paralytic symptoms in patients injected with botulinum toxin for therapeutic or cosmetic effect, are rare and without epidemic potential.
Botulinum toxin, of which 7 serotypes (designated by letters A-G) have been identified, causes a descending paralysis by irreversibly blocking the release of acetylcholine at the neuromuscular junction. Botulinum toxin has been part of state-sponsored biological weapons programs, and both the toxin and bacteria capable of producing it are classified as select agents subject to federal regulations (42 CFR Part 73) [3, 4] . Because of its severity and outbreak potential through the foodborne route, a single case of botulism is considered a public health emergency [5, 6] .
Botulism is characterized by cranial nerve palsies followed by descending flaccid paralysis [7] . Respiratory compromise and death may result from paralysis of the diaphragm, accessory respiratory muscles, or muscles that maintain upper airway patency, unless mechanical ventilation is initiated [4] . In foodborne botulism, nerve palsies may be preceded by acute gastrointestinal symptoms. The rate and extent of paralysis progression varies and is likely dose dependent [5] . Paralysis generally resolves in weeks to months [5] .
Traditional laboratory testing for botulism uses a toxin neutralization bioassay for clinical or food specimens in mice, and may take up to 10 days. Polymerase chain reaction (PCR) assay and enzyme-linked immunosorbent assay (ELISA) are available to detect botulinum toxin in clinical specimens, and the organism can be cultured; however, these tests also take several days to complete. Therefore, the key therapeutic intervention in botulism, rapid administration of antitoxin, in almost all cases is undertaken based on clinical diagnosis alone [8, 9] .
Rapid antitoxin administration and meticulous intensive care, including respiratory monitoring, mechanical ventilation, and nutritional support when required, are the cornerstones of botulism treatment [7] [8] [9] . Various equine-derived antitoxin preparations have been available in the past. In the United States, the currently available antitoxin is a heptavalent preparation that contains antibodies against 7 types of botulinum toxin. Antitoxin neutralizes circulating toxin but does not reverse paralysis; therefore, heptavalent antitoxin should be administered as soon as the diagnosis is suspected, and supportive care is required until pretreatment deficits have resolved [8] . Equine antitoxin administration may result in adverse events, including anaphylaxis during first or subsequent doses [10] . Infant botulism is treated with low-titer human-derived antitoxin licensed in the United States for treatment of infant botulism types A and B [11] .
Foodborne botulism or wound botulism can affect persons of any age, but most cases occur in adults; the clinical presentation, diagnosis, and response to treatment of botulism in children are not well described. The purpose of this systematic review is to determine what signs and symptoms are of diagnostic value in children with botulism and to describe the effect of botulinum antitoxin administration in children. Additional detail on the use and efficacy of botulinum antitoxin in children may be found in the articles by O'Horo et al and Yu et al in this supplement [12, 13] .
METHODS

Protocol and Registration
The systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) statement (http://www.prisma-statement.org/) and registered with the International Prospective Register of Systematic Reviews (PROSPERO; number CRD42015024804).
Eligibility Criteria
Analytic studies, case reports, and case series with primary data on botulism in children (persons aged <18 years) or on administration of equine botulinum antitoxin to children were considered for inclusion. The Council of State and Territorial Epidemiologists 2011 case definitions for botulism were utilized for case classification (https://wwwn.cdc.gov/nndss/ conditions/botulism/case-definition/2011/). A confirmed case of botulism was defined as a clinically compatible illness with laboratory confirmation, as reported by the authors. For foodborne botulism, a confirmed case was also defined as a clinically compatible illness in a person who ate the same implicated food as a person with a laboratory-confirmed case. Wound botulism was defined as a clinically compatible illness in a person with a recent open wound or injection drug use. Probable cases utilized the same definitions, but without laboratory confirmation.
Reports were eligible for inclusion if published in peer-reviewed or non-peer-reviewed (eg, Morbidity and Mortality Weekly Report) journals in any language from any year. Reports were excluded if they did not include primary data on botulism or antitoxin use in children, did not provide case-specific information, or if they described therapeutic botulinum toxin use not resulting in systemic intoxication. Infant botulism reports were included only if equine antitoxin was administered to the infant. All studies and reports were systematically evaluated to identify the disease course and outcomes, and use and adverse events of equine antitoxin in children. Primary outcomes of the review included morbidity, mortality, length of hospital stay, duration of ventilator dependence, and serious adverse events from botulinum antitoxin. Center (DTIC) and government documents via WorldCat, and DTIC documents via Google Scholar. Search terms focused on botulism, botulinum antitoxin, and pediatrics. Additionally, reference lists of relevant reports were hand-searched and botulism subject matter experts were consulted. The full search strategy may be accessed here: http://www.crd.york.ac.uk/ PROSPEROFILES/24804_STRATEGY_20150623.pdf.
Information Sources and Searches
A Centers for
Study Selection
Two independent reviewers screened search results by title and abstract. Discordant decisions were discussed and adjudicated. Reports that passed initial screening underwent full text review by 2 independent reviewers to assess eligibility. Discordant decisions were discussed and adjudicated ( Figure 1 ).
Non-English article title and abstract screening was done by linguistically proficient individuals or by Google Translate (https://translate.google.com/). Reports included in the full text review were professionally translated into English.
Data Collection and Quality Assessment
A data abstraction tool was developed in Epi Info 7 and included checklists for assessing bias and study quality, including a modified US Preventive Services Task Force (USPSTF) Hierarchy of Evidence Category Grade to assess study design, a modified Newcastle-Ottawa Scale (NOS) to assess level of certainty and risk of bias, and a data completeness score [14, 15] . Two clinicians abstracted data and assessed the quality of the studies included. Abstracted data included patient demographic information, toxin serotype, transmission type (eg, foodborne), clinical signs and symptoms, diagnostics and imaging, level of care provided, interventions, antitoxin type and dose, adverse events, and patient outcomes.
Data Synthesis and Analysis
Data were extracted from Epi Info 7 into Microsoft Excel for cleaning and de-duplication. Analyses were conducted using SAS software, version 9.4 (SAS Institute, Cary, North Carolina). A 1-way analysis of variance was calculated for disease progression and hospitalization trends across age groups. The χ 2 test
and relative risk were used to assess outcomes; Mantel-Haenszel χ 2 test was utilized to assess outcomes by age group, due to small sample sizes. Statistical significance was set at α = .05.
RESULTS
Study Selection and Case Identification
A total of 7065 reports were identified through literature review (n = 7036) and expert recommendation (n = 29). Duplicate reports were removed (n = 1524); remaining reports underwent title and abstract screening for eligibility. Full text review was performed on 509 reports; 349 were excluded and 24 new reports were identified from references. A total of 184 reports met inclusion criteria. Each case described in a report was abstracted separately; 406 cases were identified (Table 1) . Duplicate cases were identified and combined (n = 32), for a total of 374 unique pediatric cases ( Figure 1 ).
Data Quality
All included reports were category III (case reports or case series) in the USPSTF Hierarchy of Evidence for study design, the lowest level of internal validity. On the 0-12 modified NOS for certainty and risk of bias, the median score was 6 (range, 0-10); 12 represents highest quality. Data completeness scores assessed the presence of 15 elements and were categorized as detailed and precise (13) (14) (15) , somewhat detailed (9-12), or cursory (1-8); the median score was 9 (range, 2-14).
Case Description
Of reported a specific food as the suspected source of botulism, though in most cases it was unclear if toxin was detected in the food. The suspected food was a canned food for 138 (45%) cases, a home canned product for 91 (29%), a meat product (including seafood) for 153 (49%) cases, and a home prepared meat product such as sausage or smoked ham for 54 (17%) cases.
Signs and Symptoms
Several signs and symptoms typical of botulism-cranial nerve palsies and muscle paralysis-were reported in children with botulism; dysphagia was present in more than half the cases and dysarthria, generalized weakness, double vision, and ptosis in more than a third (Table 3) . Among cases that reported ptosis, dilated pupils, descending paralysis, or facial drooping, unilateral presentation was noted in a small minority (<6 cases per sign).
Signs and symptoms did not differ with statistical significance between age groups; however, certain findings were notable. Dysphagia was the most commonly reported symptom in each age group, except for cases aged <1 year. The 3 foodborne botulism cases reported in infants were characterized by poor feeding, weak cry, hypotonia, fixed or dilated pupils, constipation, apnea, and lethargy. Double vision was uncommonly reported among cases aged <5 years; however, it was reported in >30% of cases aged 5 to <18 years, and frequency increased with age.
Dysphagia, dysarthria, and generalized weakness were the 3 most commonly reported signs and symptoms among pediatric botulism cases aged 1 to <10 years. Ptosis, dilated pupils, fixed pupils, and vomiting were also present in >30% of cases in these age groups.
Dysphagia, dysarthria, and double vision were the 3 most commonly reported signs and symptoms among cases aged 10 to <18 years, followed by generalized weakness. Ptosis, dry mouth, and ataxia were also reported for >30% of cases in this age range.
Incubation period could be calculated for 210 (58%) cases. Time from suspected exposure to onset of the first sign or symptom ranged from 0 to 17 days (median, 1 day). Incubation period did not differ by age group (P = .71). Progression from onset of first sign or symptom to onset of first neurological sign or symptom could be calculated for 162 (45%) cases. Most cases (n = 133 [82%]) had first neurological sign or symptom onset on the first day of illness; 6 cases had onset ≥4 days later.
Progression from illness onset to first neurological sign or symptom did not differ by age group (P = .11).
Differential Diagnoses
A differential diagnosis was reported in 79 (22%) cases; myasthenia gravis (n = 22 [28%]), poisonings and intoxications (n = 45 [25%]), Guillain-Barré syndrome (n = 11 [14%]), and poliomyelitis (n = 9 [11%]) were most commonly listed as alternate diagnoses considered.
Diagnostic Testing and Imaging
Botulism was diagnosed by utilizing the animal bioassay in 255 (71%) cases, culture in 120 (33%) cases, immuno-PCR in 5 (1%) cases, and ELISA in 4 (1%) cases. Some cases were tested by >1 method. Specimen source (clinical or food) was infrequently reported by authors. Among cases for whom a diagnostic test was performed, a positive result was reported for 205 (80%) animal bioassays, 93 (78%) cultures, 5 (100%) immuno-PCR assays, and 2 (50%) ELISAs. Electromyography (EMG) was conducted in 56 (16%) cases, nerve conduction studies in 16 (4%) cases, and Tensilon tests in 8 (2%) cases. Abnormalities were reported by the authors for 46 cases (82%) who underwent EMG, 6 (36%) who had nerve conductions studies, and none of the 8 who had Tensilon tests.
Additional diagnostic and imaging procedures included the following: Lumbar puncture was documented in 51 (14%) cases, with generally nonspecific findings. Computed tomography and magnetic resonance imaging of brain and spine were performed infrequently (n = 29); abnormal findings (n = 3) were few and nonspecific (mild brain edema, n = 2) or attributed to chronic, underlying conditions (n = 1).
Clinical Course
Medical care was sought for 288 (80%) cases; 54 (19%) of these were seen as outpatients. Among 11 cases for which the number was available, outpatient encounters occurred once per patient (8 cases), twice (2 cases), or thrice (1 case). In 6 cases, patients reported receiving outpatient care only, with no inpatient care; 5 (83%) of these children died. Nine additional patients were seen as outpatients, with inpatient care not specified; 7 (78%) of these children died. For most cases (n = 270 [75%]), patients received inpatient care (Figure 3 ) for a median duration of 24 days (range, 1-425 days). Intensive care unit (ICU) admission was reported for 37 (14%) cases for a median duration of 14 days (range, 1-42 days). Duration of hospitalization (P = .40) and ICU stay (P = .56) did not differ significantly by age group.
Mechanical ventilation was reported in 91 (25%) cases for a median of 17 days (range, 1-259 days). Tracheostomy was required in 31 (33%) of these cases; in 2 cases tracheostomy was placed in anticipation of mechanical ventilation, which ultimately was not required. Median duration of tracheostomy use was 38 days (range, 8-90 days).
Antitoxin
Botulinum antitoxin was administered to 193 patients: 179 pediatric botulism cases, 3 infant botulism cases, and 11 nonbotulism cases. A median of 2 doses (range, 1-9) were given 
Outcomes
Of 270 hospitalized cases, disposition among those surviving to discharge was specified for 41 (15%); of these, 34 (83%) were discharged home without inpatient or outpatient rehabilitation, and 7 (17%) were discharged to rehabilitation centers.
Of the 360 pediatric botulism patients, 83 (23%) died. Case fatality rates did not vary significantly by age group (Table 4) The time interval from illness onset to death could be calculated for 44 (53%) cases. Median interval was 1 day (range, 0-260 days), and the interval did not differ significantly by age group (P = .33). The time interval from hospital admission to death could be calculated for 23 (28%) cases, with a median of 1 day (range, 0-252 days).
Among the 101 patients for whom duration of inpatient admission was known, 7 died; of these, 5 died in the first 3 days of hospitalization (Figure 3 ).
Impact of Antitoxin on Outcomes
The relative risk (RR) of death among pediatric botulism cases treated with antitoxin (n = 17 deaths) compared with those not treated with antitoxin (n = 27 deaths) was 0.24 (95% confidence interval [CI], .14-.40; P < .0001). When evaluated by age group, patients aged 1 to <5 years (RR, 0.11 [95% CI, .02-.79]; P = .028), patients aged 5 to <9 years (RR, 0.16 [95% CI, .06-.44]; P < .0004), patients aged 10 to <15 years (RR, 0.20 [95% CI, .06-.65]; P = .007), and patients aged 15 to <18 years (RR, 0.19 [95% CI, .04-.99]; P = .048) had significantly decreased relative risk of death among those who received antitoxin. The relative risk of patients aged <1 year could not be calculated (Table 4) .
DISCUSSION
Our review of botulism in children suggests that pediatric patients' clinical presentation, clinical course, and response to antitoxin treatment are similar to those described for adult patients, with a few important caveats. Clinicians are most likely to observe dysphagia, dysarthria, and generalized weakness in children with botulism. Signs and symptoms of botulism are similar across childhood age groups; however, recognition of botulism in younger children and infants requires increased reliance on clinical signs (such as ophthalmoplegia) rather than on reported symptoms (such as double vision). Progression of illness can be rapid; when respiratory compromise and death occur, it is often within a day of symptom onset. Children who receive botulinum antitoxin are more likely to survive. The clinical presentation of botulism is classically described as cranial nerve palsies followed by bilateral descending flaccid paralysis; in children, the most common manifestations in our study were cranial nerve-related dysphagia, dysarthria, and generalized weakness more than paralysis. These signs and symptoms were consistent across age groups, with the corresponding presentation in infants described as poor feeding (potentially a manifestation of dysphagia), weak cry, and hypotonia. Of note, an alert infant with hypotonia, ptosis, and fixed pupils may be mischaracterized as being lethargic. Eye findings, including double vision, ptosis, dilated pupils, and fixed pupils, were also common; however, signs were more common than symptoms in younger children. Younger children may not be able to articulate the symptoms they are experiencing, such as double vision or dry mouth, leading these symptoms to be underreported in younger age groups. Clinicians should recognize that children <10 years of age may present with dysphagia, dysarthria, generalized weakness, ophthalmoplegia, and vomiting, while children aged ≥10 years of age may complain of dysphagia, dysarthria, double vision, generalized weakness, ptosis, and dry mouth. Reported ataxia likely represents weakness or blurry vision, as botulism does not affect the cerebellum.
Progression of illness can be rapid in children with botulism. The incubation period for most cases was 1 day and most deaths occurred within 1 day of illness onset. This highlights the importance of early clinical suspicion for botulism, provision of meticulous intensive care, and administration of botulinum antitoxin as soon as possible. Laboratory testing might subsequently confirm the diagnosis, but treatment should be initiated based on clinical diagnosis.
We found that equine antitoxin administration to children with botulism reduced mortality by 76% and that adverse events associated with antitoxin administration were infrequent and mostly minor. Serious adverse events including serum sickness, anaphylaxis, and cardiovascular collapse leading to 1 death occurred but were relatively rare. We note that antitoxin preparations in this study were reports from over the course of 9 decades in 35 countries and varied in valence, antigenicity, concentration, and neutralizing capacity. We did not seek to determine optimal antitoxin dose or timing of administration. Our findings support current CDC recommendations to administer antitoxin to patients with suspected botulism as soon as possible [16] .
Caring for children with botulism can be resource intensive, even when antitoxin is administered early in the course of illness. Children require a high level of care and frequent monitoring. Most cases in our review required inpatient care lasting weeks, and a subset of these required ICU admission. Mechanical ventilation, when required, was prolonged and tracheostomy frequent. It is essential that medical and nursing staff recognize that children with botulism may be alert, despite their inability to move, speak, or breathe and that appropriate psychological support measures be instituted.
This study is subject to at least 3 limitations. First, information collected by this study consisted of author reports in published journals. Reporting standards may have varied by journal, geographic region (35 countries represented), and decade (reports spanned the years 1927-2015). Diagnostic criteria for botulism, including laboratory methods, may also vary by geography and time period. Second, medical care, particularly intensive and critical care, vastly changed over the time period covered by this review; mechanical ventilation entered medical practice halfway through the period covered. The outcomes we describe are averaged over nearly a century. Pediatric mortality over the entire time period of this review was 23%, which is similar to historical fatality rates for adult botulism [17] , but different than current all-age mortality from botulism in the United States which is <3% [18] . Fatality rates in pediatric botulism in the most current time period of our review are in line with the current all-age mortality in the United States. Third, publication bias may have favored cases of botulism with unusual presentation or greater severity. This review does not represent active surveillance data.
Children with botulism are more likely to survive when treated rapidly with botulinum antitoxin. In the United States, a physician suspecting botulism in a child should immediately call the state public health department emergency phone number. The state will connect the physician to CDC's 24-hour Botulism Clinical Consultation Service for a telephone consult by a botulism expert and, when indicated, immediate shipment of botulinum antitoxin from the Strategic National Stockpile to the patient's bedside. 
